Literature DB >> 25964867

Mutant IDH1: An immunotherapeutic target in tumors.

Theresa Schumacher1, Lukas Bunse1, Wolfgang Wick2, Michael Platten1.   

Abstract

The discovery of driver mutations in cancers has raised interest in their suitability as immunotherapeutic targets. A recent study demonstrates that a point mutation in isocitrate dehydrogenase 1 (IDH1R132H), expressed in gliomas and other tumors, is presented on human MHC class II and induces a mutation-specific CD4+ antitumor T cell response in patients and a syngeneic tumor model in MHC-humanized mice.

Entities:  

Keywords:  IDH1 mutation; MHC class II epitope; MHC-humanized mice; cancer immunotherapy; glioma; mutation-specific CD4+ T-cells

Year:  2015        PMID： 25964867      PMCID： PMC4353168          DOI： 10.4161/2162402X.2014.974392

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  9 in total

1.  Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.

Authors:  John H Sampson; Amy B Heimberger; Gary E Archer; Kenneth D Aldape; Allan H Friedman; Henry S Friedman; Mark R Gilbert; James E Herndon; Roger E McLendon; Duane A Mitchell; David A Reardon; Raymond Sawaya; Robert J Schmittling; Weiming Shi; James J Vredenburgh; Darell D Bigner
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

Review 2.  Microenvironmental clues for glioma immunotherapy.

Authors:  Michael Platten; Katharina Ochs; Dieter Lemke; Christiane Opitz; Wolfgang Wick
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

3.  A vaccine targeting mutant IDH1 induces antitumour immunity.

Authors:  Theresa Schumacher; Lukas Bunse; Stefan Pusch; Felix Sahm; Benedikt Wiestler; Jasmin Quandt; Oliver Menn; Matthias Osswald; Iris Oezen; Martina Ott; Melanie Keil; Jörg Balß; Katharina Rauschenbach; Agnieszka K Grabowska; Isabel Vogler; Jan Diekmann; Nico Trautwein; Stefan B Eichmüller; Jürgen Okun; Stefan Stevanović; Angelika B Riemer; Ugur Sahin; Manuel A Friese; Philipp Beckhove; Andreas von Deimling; Wolfgang Wick; Michael Platten
Journal:  Nature       Date:  2014-06-25       Impact factor: 49.962

Review 4.  Tryptophan catabolism in cancer: beyond IDO and tryptophan depletion.

Authors:  Michael Platten; Wolfgang Wick; Benoît J Van den Eynde
Journal:  Cancer Res       Date:  2012-10-22       Impact factor: 12.701

5.  Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.

Authors:  Sergio A Quezada; Tyler R Simpson; Karl S Peggs; Taha Merghoub; Jelena Vider; Xiaozhou Fan; Ronald Blasberg; Hideo Yagita; Pawel Muranski; Paul A Antony; Nicholas P Restifo; James P Allison
Journal:  J Exp Med       Date:  2010-02-15       Impact factor: 14.307

Review 6.  Adoptive immunotherapy of cancer using CD4(+) T cells.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Curr Opin Immunol       Date:  2009-03-13       Impact factor: 7.486

7.  Recurring mutations found by sequencing an acute myeloid leukemia genome.

Authors:  Elaine R Mardis; Li Ding; David J Dooling; David E Larson; Michael D McLellan; Ken Chen; Daniel C Koboldt; Robert S Fulton; Kim D Delehaunty; Sean D McGrath; Lucinda A Fulton; Devin P Locke; Vincent J Magrini; Rachel M Abbott; Tammi L Vickery; Jerry S Reed; Jody S Robinson; Todd Wylie; Scott M Smith; Lynn Carmichael; James M Eldred; Christopher C Harris; Jason Walker; Joshua B Peck; Feiyu Du; Adam F Dukes; Gabriel E Sanderson; Anthony M Brummett; Eric Clark; Joshua F McMichael; Rick J Meyer; Jonathan K Schindler; Craig S Pohl; John W Wallis; Xiaoqi Shi; Ling Lin; Heather Schmidt; Yuzhu Tang; Carrie Haipek; Madeline E Wiechert; Jolynda V Ivy; Joelle Kalicki; Glendoria Elliott; Rhonda E Ries; Jacqueline E Payton; Peter Westervelt; Michael H Tomasson; Mark A Watson; Jack Baty; Sharon Heath; William D Shannon; Rakesh Nagarajan; Daniel C Link; Matthew J Walter; Timothy A Graubert; John F DiPersio; Richard K Wilson; Timothy J Ley
Journal:  N Engl J Med       Date:  2009-08-05       Impact factor: 91.245

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

Review 9.  Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities.

Authors:  Rob A Cairns; Tak W Mak
Journal:  Cancer Discov       Date:  2013-06-24       Impact factor: 38.272
  9 in total
  17 in total

Review 1.  Glioblastoma antigen discovery--foundations for immunotherapy.

Authors:  Tej D Azad; Seyed-Mostafa Razavi; Benjamin Jin; Karen Lee; Gordon Li
Journal:  J Neurooncol       Date:  2015-06-05       Impact factor: 4.130

Review 2.  Immunotherapy for High Grade Gliomas: A Clinical Update and Practical Considerations for Neurosurgeons.

Authors:  Jacob S Young; Fara Dayani; Ramin A Morshed; Hideho Okada; Manish K Aghi
Journal:  World Neurosurg       Date:  2019-01-21       Impact factor: 2.104

Review 3.  Vaccination strategies for neuro-oncology.

Authors:  John H Sampson; Duane A Mitchell
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

Review 4.  Vaccine Strategies in Gliomas.

Authors:  Michael Platten; Lukas Bunse; Dennis Riehl; Theresa Bunse; Katharina Ochs; Wolfgang Wick
Journal:  Curr Treat Options Neurol       Date:  2018-03-28       Impact factor: 3.598

Review 5.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

6.  A Synthetic Lethal Interaction between Glutathione Synthesis and Mitochondrial Reactive Oxygen Species Provides a Tumor-Specific Vulnerability Dependent on STAT3.

Authors:  Daniel J Garama; Tiffany J Harris; Christine L White; Fernando J Rossello; Maher Abdul-Hay; Daniel J Gough; David E Levy
Journal:  Mol Cell Biol       Date:  2015-08-17       Impact factor: 4.272

7.  In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.

Authors:  Valeria Cuccarini; Luigi Antelmi; Bianca Pollo; Rosina Paterra; Chiara Calatozzolo; Anna Nigri; Francesco DiMeco; Marica Eoli; Gaetano Finocchiaro; Greta Brenna; Irene Tramacere; Maria Grazia Bruzzone; Elena Anghileri
Journal:  Neurol Sci       Date:  2019-10-24       Impact factor: 3.307

Review 8.  Improving vaccine efficacy against malignant glioma.

Authors:  Erik Ladomersky; Matthew Genet; Lijie Zhai; Galina Gritsina; Kristen L Lauing; Rishi R Lulla; Jason Fangusaro; Alicia Lenzen; Priya Kumthekar; Jeffrey J Raizer; David C Binder; C David James; Derek A Wainwright
Journal:  Oncoimmunology       Date:  2016-06-10       Impact factor: 8.110

Review 9.  Evolving Molecular Genetics of Glioblastoma.

Authors:  Qiu-Ju Li; Jin-Quan Cai; Cheng-Yin Liu
Journal:  Chin Med J (Engl)       Date:  2016-02-20       Impact factor: 2.628

10.  Identification of a five B cell-associated gene prognostic and predictive signature for advanced glioma patients harboring immunosuppressive subtype preference.

Authors:  Chuanbao Zhang; Jiye Li; Haoyuan Wang; Sonya Wei Song
Journal:  Oncotarget       Date:  2016-11-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.